Safety and Efficacy of an Autologous Tumor Infiltrating Lymphocyte (TIL) Therapy in Patients with Advanced Solid Tumors

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 23, 2023

Primary Completion Date

February 15, 2027

Study Completion Date

June 15, 2027

Conditions
Solid Tumor
Interventions
BIOLOGICAL

BEN101

"Lymphodepletion regimen:Cyclophosphamide 250mg/ m2/day x 3 days (day -4, -3,-2) , Fludarabine 25mg/ m2/day x 2 days (day-4, -3) , Paclitaxel 100mg/ m2/day -3. The lymphodepletion regimen could be adjusted by the treating physician according to patient's disease condition.~BEN101 infusion: Single dose level between 1x10\^9 to 1x 10\^11,not lower than 1×10\^9 cells, final dose is affected by the starting amount of TILs cells isolated from the tumor tissue sample.~IL-2:Administer 8-16 hr after TIL infusion. 600,000 IU/kg intravenously over 15-20 mins every 12 hours. It is recommended to start with high dose; and de-escalate based on tolerability, up to 5 days. IL-2 administration will be terminated if unacceptable toxicities occur."

Trial Locations (3)

200125

NOT_YET_RECRUITING

RenJi Hospital, Shanghai

201620

NOT_YET_RECRUITING

Shanghai General Hospital, Shanghai

Unknown

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
collaborator

Shanghai General Hospital, Shanghai Jiaotong University School of Medicine

UNKNOWN

collaborator

RenJi Hospital

OTHER

collaborator

Fudan University

OTHER

lead

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER